From Discovery to Clinical Trials: Treatment Strategies for Central Neuropathic Pain after Spinal Cord Injury

By  

Current Pharmaceutical Design, Vol. 11, Iss. 11, 2005-04 ,pp. : 1411-4120

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological Management of Neuropathic Pain Following Spinal Cord Injury

By Baastrup Cathrine   Finnerup Nanna B.  

CNS Drugs, Vol. 22, Iss. 6, 2008-01 ,pp. : 455-475

Adis International

Access to resources Recommend Favorite

Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 10, Iss. 5, 2011-08 ,pp. : 589-609

Bentham Science Publishers

Access to resources Recommend Favorite

The very-high-efficacy 5-HT 1A receptor agonist, F 13640, preempts the development of allodynia-like behaviors in rats with spinal cord injury

By Wu W.-P.   Hao J.-X.   Xu X.-J.   Wiesenfeld-Hallin Z.   Koek W.   Colpaert F.C.  

European Journal of Pharmacology, Vol. 478, Iss. 2, 2003-10 ,pp. : 131-137

Elsevier

Access to resources Recommend Favorite

Effects of a Single Dose of Methylprednisolone versus Three Doses of Rosiglitazone on Nerve Growth Factor Levels after Spinal Cord Injury

By Meng B   Zhang Q   Huang C   Zhang HT   Tang T   Yang HL  

The Journal of International Medical Research, Vol. 39, Iss. 3, 2011-05 ,pp. : 805-814

Field House Publishing

Access to resources Recommend Favorite